Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA Hopes To Change Medicare Payment Board Even As It Applauds House-Passed Reform Package

This article was originally published in The Pink Sheet Daily

Executive Summary

The bill that cleared the House March 21 continues to include creation of an Independent Medicare Advisory Commission with broad powers for implementing cost-cutting measures in Medicare.

You may also be interested in...



IPAB’s Tough Road Ahead Shown As Republicans Opt Not To Help Find Members

House Speaker Boehner and Senate Majority Leader McConnell “respectfully decline” the president’s request to submit names of individuals to serve on the Medicare Independent Payment Advisory Board.

Beyond ObamaCare: Big Pharma, Health Reform and the 2012 Elections

Most everyone can agree that health care costs are spiraling out of control. President Obama and his Republican challenger Mitt Romney each say they have a plan to cut spending. But while those are being debated, a high-profile group of former Obama advisers are suggesting something much more radical: a systematic change in the way we pay for health care. Could it be a blueprint for a second Obama term?

Medicare Reform Using Part D Model Is Advocacy Priority For PhRMA – Castellani

For PhRMA, supporting a move toward privatizing Medicare is a tactic that may help avoid the establishment of new price controls in the system, like the often-discussed mandated drug rebates in Part D.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS070393

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel